By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Retailers in the U.S. are increasingly cautious due to tariffs and destocking inventories as cost-conscious consumers tighten ...

CVS released a statement to News 8 and provided more details on its investments, colleague support initiatives, and the acquisition of Rite Aid prescription files.

Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic How Gilead is helping innovate HIV prevention, removing stigma and empowering Black women.

AbbVie, Gilead and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the viruses.

Brazilian state-run oil firm Petrobras said on Wednesday that chairman Pietro Mendes has resigned from the role, as well as from his seat on the board of directors. Mendes is set to become a director ...